Recent studies have highlighted the therapeutic potential of targeting ApoE4, with one such study finding that ApoE immunotherapy was able to ameliorate amyloid-related pathology and protect cerebrovascular function in a mouse model of AD [44]. This evidence concerns the gene APOE and amyloidosis.